Shizim Group

What Shizim Group does

Shizim Group is a privately-held Israeli Life Sciences and Health Tech holding group founded in 2000 by Yossi Bornstein, the former CEO of Bristol-Myers Squibb in Israel, and headquartered in Rosh Ha'ayin. The group operates a diversified platform of seven core subsidiaries across the biomedical value chain: ShizimXL, ShizimVS and Eyelon serve as MedTech, digital health and ophthalmology innovation centers, respectively, providing incubation, mentorship, regulatory and go-to-market support to startups; GCP Clinical Studies is a full-service Contract Research Organization running clinical studies for multinational pharmaceutical and medical device companies; Dolphin Medical distributes medical devices into Israeli hospitals, medical centers and pharmacy chains; Biotis represents international pharma partners with regulatory, reimbursement, marketing and distribution services; and Cann10 (in which Shizim became the major shareholder in December 2020) holds an Israeli medical cannabis production and trade license and operates across more than 10 countries. The group also runs education programs, including GCP Academy and a Medical Device Development Course, in collaboration with the Technion.

Shizim's underlying technology stack is portfolio-based rather than a single proprietary platform. It includes the XACT ACE hands-free robotic system for image-guided percutaneous procedures (developed from Technion research by Moshe Shoham and FDA-cleared in July 2020), ophthalmic innovation assets held via Eyelon, and digital health ventures built by ShizimVS in collaboration with Sourasky, Rambam and Technion. Notable historical outcomes include the NASDAQ listing of portfolio company Microbot Medical (MBOT) and FDA/CE approval plus US sales-stage commercialization of XACT Robotics. The group reports international strategic partnerships across the US, Europe and China, formalized through a 2020 collaboration agreement with the Research Institute of Tsinghua University in Shenzhen (RITS).

Shizim's business model combines professional services revenue (CRO contracts via GCP, mentoring and program fees at the innovation centers), product distribution margins (Dolphin Medical and Biotis), product sales and licensing in medical cannabis (Cann10), and equity-driven upside from portfolio company exits and licensing. The group markets through direct B2B relationships, industry conferences, a newsletter published since 2011, and LinkedIn rather than paid digital channels. Customers include multinational pharma and medical device companies, Israeli health funds, hospitals, medical centers, pharmacy chains, geriatric centers, and early-stage MedTech and digital health startups.

Name

Shizim Group

Legal name

Shizim Group

Website

https://shizim.com

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

51–100 employees

Short description

Shizim Group is a privately-held Israeli Life Sciences and Health Tech holding group operating innovation centers (ShizimXL, ShizimVS, Eyelon), a CRO (GCP Clinical Studies), pharmaceutical and medical device distributors (Biotis, Dolphin Medical), a medical cannabis operation (Cann10), and education programs in collaboration with the Technion.

Ownership category

akta.pro rank

Headquarters

HQ city

Rosh Ha'ayin

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Others

Revenue model

1. Contract Research Organization (CRO) Services: GCP Clinical Studies Ltd. provides full-service CRO capabilities coordinating all aspects of clinical studies for pharmaceutical and medical device companies. Revenue generated from clinical trial management services.
2. Medical Device Distribution: Dolphin Medical distributes medical devices including mesh implants, sterile wound irrigation, rectal biopsy solutions, hemostats and other medical devices to hospitals, medical centers and pharmacy chains. Revenue from product distribution margins.
3. Pharmaceutical Distribution: Biotis represents international pharmaceutical partners, providing regulatory approvals, national reimbursement, strategic marketing, import, sales and distribution of ethical drugs to pharmacies, hospitals, Israeli health funds and geriatric centers.
4. Medical Cannabis Operations: Cann10 operates in medical cannabis including growing, producing, marketing, and global trade across 10+ countries. Licensed in Israel to produce and trade medical cannabis. Revenue from product sales and potentially licensing.
5. Innovation Center Investments: ShizimXL and ShizimVS provide innovation center services, mentoring, and support for MedTech startups. Revenue model includes equity stakes in portfolio companies and potential licensing/success fees from exits.
6. Education and Training Programs: GCP Academy and E-Center provide advanced education and training programs for medical professionals, investors and entrepreneurs in collaboration with Technion.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

Shizim Group is an integrated Life Sciences and Health Tech holding group operating innovation centers (ShizimXL, ShizimVS, Eyelon), service companies (GCP Clinical Studies CRO, Dolphin Medical device distribution, Biotis pharmaceutical distribution, Cann10 medical cannabis), and education programs (GCP Academy). It identifies MedTech and Digital Health startups, provides regulatory and clinical support, and offers pharmaceutical and medical device distribution across Israel and globally.

Product overview

Shizim Group is Israel's leading integrated Life Sciences and Health Tech holding group operating as a platform of multiple innovation centers, service companies, and education programs. The ecosystem comprises: ShizimXL (MedTech innovation accelerator), ShizimVS (Digital Health Venture Studio), and Eyelon (Ophthalmic Innovation Center) for startup incubation and development; GCP Clinical Studies (full-service CRO), Dolphin Medical (device distributor), Biotis (pharmaceutical representation), and Cann10 (medical cannabis) for commercial services; plus GCP Academy and Medical Device Development Course for professional education. Notable portfolio companies include Microbot Medical (LIBERTY Surgical Robot, NASDAQ: MBOT) and XACT Robotics (ACE Robotic System with FDA/CE approval).

Differentiator

Problem solved

Functional benefit

Products and services

• ShizimXL Innovation center that identifies and onboards disruptive MedTech innovations, nurturing startups from early-stage ideas to proof-of-concept, product development, strategic partnerships, and funding with 20+ industry expert mentors.
• ShizimVS Digital Health Venture Studio that identifies unmet needs in healthcare and assigns expert teams to address these needs with innovative digital technologies, leveraging collaborations with leading medical and academic centers.
• Eyelon Ophthalmic Innovation Center that identifies and invests in novel breakthrough Ophthalmic startup technologies, founded and managed in partnership with Professor Alon Harris.
• GCP Clinical Studies Ltd. Leading privately owned full-service Contract Research Organization (CRO) coordinating all aspects of clinical studies for multinational Pharma and Medical Device companies.
• Dolphin Medical Highly respected distributor of medical devices offering registration, importation, distribution, reimbursement and sales services to hospitals, medical centers and pharmacy chains.
• Biotis Focused on the Israeli bio-pharmaceutical industry, offering regulatory approvals, national reimbursement, strategic marketing, import, sales and distribution of ethical drugs to pharmacies, hospitals, Israeli health funds and geriatric centers.
• Cann10 Active member of the medical cannabis industry with offices in more than 10 countries, licensed in Israel to produce and trade medical cannabis, involved in growing, producing, marketing, and global trade.
• GCP Academy Advanced education and training programs for medical professionals, investors and entrepreneurs in collaboration with the Technion (Israel Institute of Technology).
• Medical Device Development Course Professional course for medical device development offered as part of Shizim Group's education and training offerings in collaboration with the Technion.

Quantifiable outcome

• Successfully exited Microbot Medical to NASDAQ (MBOT)
• +1 more outcomes

Named customers6 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

14 partnerships are on record, tiered core and minor.

• Technion - Israel Institute of TechnologycoreStrategic or Co-development PartnerCollaboration with Technion for education and training programs. Technion provides academic expertise and facilities for medical professional training programs offered by Shizim Group's education centers.
• Tel Aviv Sourasky Medical Center (Ichilov Hospital)coreStrategic or Co-development PartnerCollaboration with Tel Aviv Sourasky Medical Center for ShizimVS Digital Health Venture Studio. Medical center provides first-hand user needs, testing and feedback throughout the development process for digital health innovations.
• Rambam Medical CentercoreStrategic or Co-development PartnerCollaboration with Rambam Medical Center in Haifa for ShizimVS. Medical center provides unmet needs identification and feedback for digital health solution development.
• Professor Alon Harris (Eyelon)coreStrategic or Co-development PartnerEyelon Ophthalmic Innovation Center founded and managed in partnership between Professor Alon Harris (internationally recognized expert in Ophthalmology) and Shizim Group. Partnership facilitates identification and investment in breakthrough Ophthalmic startup technologies.
• Tel Aviv UniversityminorStrategic or Co-development PartnerListed as a partner institution with collaboration in biomedical ecosystem activities.
• Cube Labs / RITSminorStrategic or Co-development PartnerListed as strategic partners in the Shizim Group ecosystem.
• CDSminorStrategic or Co-development PartnerListed as strategic partner in newsletter communications.
• RITS - Research Institute of Tsinghua University in Shenzhen, ChinacoreStrategic or Co-development PartnerShizim Group and RITS signed a collaboration agreement for joint innovation and research activities in the biomedical field with Chinese strategic partners.
• PromedossminorChannel Partner/ Reseller/ DistributorListed as strategic partner in newsletter and news sections.
• Ernst & Young (EY)minorImplementation/ SI/ Consulting PartnerProfessional services partner providing advisory and consulting support.
• Extera PartnersminorStrategic or Co-development PartnerListed as strategic partner in newsletter communications.
• RS-NessminorStrategic or Co-development PartnerListed as strategic partner in newsletter and news sections.
• Shibolet Law FirmminorImplementation/ SI/ Consulting PartnerLegal advisory partner for Shizim Group ecosystem.
• Global Strategic Partners (US, Europe, China)coreStrategic or Co-development PartnerPartnerships with global strategic partners across US, Europe, China and other countries enabling startups to access international markets, grants and investment opportunities.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Trendlines Group: Israeli-listed medical device and agrifood technology incubator. Closest direct comparable — runs innovation centers nurturing Israeli MedTech startups from concept through exit, exactly like ShizimXL, and competes for the same Technion/Israeli hospital deal flow.
• Hadasit Bio-Holdings: Israeli life-sciences holding company commercializing intellectual property from Hadassah Medical Center. Mirrors Shizim's model of bundling multiple biomed assets under a single corporate platform with hospital and academic partnerships.
• Clal Biotechnology Industries: Israeli biomedical holding company that invests in, incubates, and supports life-sciences companies. Operates the same holding-plus-portfolio model in Israeli biomed and serves as a direct alternative to Shizim for portfolio companies seeking a parent.

Emerging players

• Biolight Life Sciences: Israeli biomedical investment and incubation company. Smaller and earlier-stage than Shizim but addresses a similar thesis of bundling Israeli life-sciences assets under a single corporate vehicle.
• OurCrowd: Israel-based global investment platform with a dedicated healthcare/biomed portfolio. Comparable as an Israeli venture platform that competes for medtech deal flow and partners with multinationals, though structured as a fund rather than a holding group.

Broad incumbents

• Elbit Imaging (now Elbit): Israel-headquartered diversified holding group that historically operated in healthcare alongside other verticals. Comparable as a larger, more diversified Israeli holding group, though with a much broader sector mix.
• Medpace Holdings: Mid-to-large global CRO serving pharma and medical device companies. Directly comparable to Shizim's GCP Clinical Studies subsidiary as a clinical-trial services competitor, though with substantially greater scale.
• IQVIA: World's largest CRO and life-sciences services company. Provides the high-end competitive reference for GCP Clinical Studies' service offering and the broader clinical-research services market Shizim targets.
• Tilray Brands: Large multinational medical and adult-use cannabis company with global cultivation, production, and trade operations. Comparable to Shizim's Cann10 subsidiary in cross-border medical cannabis trade across multiple jurisdictions.

Others

• Parexel International: Global full-service CRO with deep pharma and MedTech clinical study operations. Comparable to GCP Clinical Studies in service scope and multinational Pharma client base.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat6 records

Key risks1 record

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/shizim-group

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Shizim Group